Healthcare, biotechnology & medical AI Product
HeartFlow FFRct estimates coronary flow measures from previous CT images
HeartFlow’s software uses previously acquired coronary CT images to estimate fractional flow reserve, a measure used in functional assessment of the coronary arteries. [1][2]
What it does
The FDA granted a De Novo request for HeartFlow FFRCT under DEN130045 on November 26, 2014. It later cleared HeartFlow Analysis under K190925 on August 15, 2019. [1][2]
Why it matters
The documents establish a role for quantitative post-processing of coronary CT. The product adds an estimate of functional information to the anatomical study. [1][2]
Who it’s for
The labeled results are intended to support qualified clinicians evaluating coronary arteries in the specified setting. [1][2]
Key dates
Where it fits
The software derives calculated fractional-flow-reserve values from the acquired images for professional review. [1][2]
Limits and trade-offs
The filings apply to the named devices and labeled settings. The software output is an adjunct to clinician interpretation. [1][2]
Sources and verification
Catalog evidence checked How we verify records
- Primary source FDA De Novo decision for HEARTFLOW FFRCT (DEN130045)
- Primary source FDA 510(k) decision for HeartFlow FFRct Analysis (K190925)
Related profiles
Healthcare, biotechnology & medical AI
Sleep Analysis Module (SAM)
Neurotronics (Nihon Kohden)
The module estimates sleep time from a signal captured during its intended sleep-testing workflow.
Healthcare, biotechnology & medical AI
Heartvue.Proton
Heartvue.ai
It is software for analyzing cardiac MRI images within its documented intended-use scope.
Healthcare, biotechnology & medical AI
ThinkSono Guidance
ThinkSono
Provides guidance during acquisition of lower-extremity compression ultrasound images for review by healthcare professionals.